Find Regorafenib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

100RELATED EXCIPIENT COMPANIES

162EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 755037-03-7, Bay 73-4506, Stivarga, 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-n-methylpicolinamide, Regorafenibum, Regorafenib (bay 73-4506)
Molecular Formula
C21H15ClF4N4O3
Molecular Weight
482.8  g/mol
InChI Key
FNHKPVJBJVTLMP-UHFFFAOYSA-N
FDA UNII
24T2A1DOYB

Regorafenib
Regorafenib is the anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.
Regorafenib is a Kinase Inhibitor. The mechanism of action of regorafenib is as a Protein Kinase Inhibitor, and Cytochrome P450 2C9 Inhibitor.
1 2D Structure

Regorafenib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
2.1.2 InChI
InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
2.1.3 InChI Key
FNHKPVJBJVTLMP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
2.2 Other Identifiers
2.2.1 UNII
24T2A1DOYB
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

2. Bay 73-4506

3. Bay-73-4506

4. Bay73-4506

5. Stivarga

2.3.2 Depositor-Supplied Synonyms

1. 755037-03-7

2. Bay 73-4506

3. Stivarga

4. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-n-methylpicolinamide

5. Regorafenibum

6. Regorafenib (bay 73-4506)

7. Bay73-4506

8. Bay-73-4506

9. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide

10. Regorafenib-13c-d3

11. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide

12. 24t2a1doyb

13. Chembl1946170

14. Chebi:68647

15. Bay-734506

16. Stivarga (tn)

17. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

18. Regorafenib [inn]

19. Regorafenib [usan:inn]

20. Unii-24t2a1doyb

21. Fluoro-sorafenib

22. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

23. Regorafenib [mi]

24. Regorafenib (usan/inn)

25. Regorafenib [vandf]

26. Regorafenib Anhydrous

27. Regorafenib [who-dd]

28. Mls006010303

29. Regorafenib Crystalline Form I

30. Schembl432230

31. Regorafenib,bay 73-4506

32. Gtpl5891

33. Dtxsid60226441

34. Ex-a058

35. Regorafenib - Bay 73-4506

36. Bcpp000352

37. Hms3654k16

38. Hms3672e15

39. Bcp02105

40. Bkd17855

41. Zinc6745272

42. Bdbm50363397

43. Mfcd16038047

44. Nsc763932

45. Nsc800865

46. S1178

47. Akos015951107

48. Am81251

49. Bay 734506

50. Bcp9000384

51. Ccg-269571

52. Cs-0170

53. Db08896

54. Nsc-763932

55. Nsc-800865

56. Sb16819

57. Ncgc00263138-01

58. Ncgc00263138-13

59. Ncgc00263138-19

60. 2-pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-n-methyl-

61. 835621-08-4

62. Ac-25075

63. Ac-31116

64. As-16304

65. Hy-10331

66. Smr004701370

67. Ft-0674338

68. R0142

69. Sw218097-2

70. Cas:835621-07-3;regorafenib Hydrochloride

71. Regorafenib (bay73-4506,fluoro-sorafenib)

72. A25020

73. D10138

74. Ab01565826_02

75. Sr-01000941571

76. Q3891664

77. Sr-01000941571-1

78. Brd-k16730910-001-02-4

79. 2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-n-methyl-

80. 4-[4-({[4-chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide

81. 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic Acid Methylamide

82. Regorafenib;1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 482.8 g/mol
Molecular Formula C21H15ClF4N4O3
XLogP34.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count5
Exact Mass482.0768807 g/mol
Monoisotopic Mass482.0768807 g/mol
Topological Polar Surface Area92.4 Ų
Heavy Atom Count33
Formal Charge0
Complexity686
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameStivarga
PubMed HealthRegorafenib (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelStivarga (regorafenib) has the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:Regorafenib is a monohydrate and...
Active IngredientRegorafenib
Dosage FormTablet
Routeoral; Oral
Strength40mg
Market StatusPrescription
CompanyBayer Healthcare Pharms; Bayer Hlthcare

2 of 2  
Drug NameStivarga
PubMed HealthRegorafenib (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelStivarga (regorafenib) has the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:Regorafenib is a monohydrate and...
Active IngredientRegorafenib
Dosage FormTablet
Routeoral; Oral
Strength40mg
Market StatusPrescription
CompanyBayer Healthcare Pharms; Bayer Hlthcare

4.2 Drug Indication

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.


FDA Label


Stivarga is indicated as monotherapy for the treatment of adult patients with:

- metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;

- unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;

- hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Active Moiety
REGORAFENIB
5.1.2 FDA UNII
24T2A1DOYB
5.1.3 Pharmacological Classes
Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]
5.2 ATC Code

L01EX05


L01XE21

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EX - Other protein kinase inhibitors

L01EX05 - Regorafenib


5.3 Absorption, Distribution and Excretion

Absorption

Cmax = 2.5 g/mL; Tmax = 4 hours; AUC = 70.4 g*h/mL; Cmax, steady-state = 3.9 g/mL; AUC, steady-state = 58.3 g*h/mL; The mean relative bioavailability of tablets compared to an oral solution is 69% to 83%.


Route of Elimination

Approximately 71% of a radiolabeled dose was excreted in feces (47% as parent compound, 24% as metabolites) and 19% of the dose was excreted in urine (17% as glucuronides) within 12 days after administration of a radiolabeled oral solution at a dose of 120 mg.


Volume of Distribution

Regorafenib undergoes enterohepatic circulation with multiple plasma concentration peaks observed across the 24-hour dosing interval.


5.4 Metabolism/Metabolites

Regorafenib is metabolized by CYP3A4 and UGT1A9. The main circulating metabolites of regorafenib measured at steady-state in human plasma are M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), both of them having similar in vitro pharmacological activity and steady-state concentrations as regorafenib. M-2 and M-5 are highly protein bound (99.8% and 99.95%, respectively). Regorafenib is an inhibitor of P-glycoprotein, while its active metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) are substrates of P-glycoprotein.


5.5 Biological Half-Life

Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);


5.6 Mechanism of Action

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib that have been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model, and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some for human colorectal carcinoma.


API SUPPLIERS

read-more
read-more

01

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Company Banner

02

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WCarrow-down NDC arrow-down KDMF arrow-down VMF Others AUDIT arrow-down
blank

03

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

04

Yangtze River Pharmaceutical Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Yangtze River Pharmaceutical Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

06

Shandong Anhong Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Shandong Anhong Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

07

Chongqing Carelife Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Chongqing Carelife Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Zhejiang Huayi Pharmaceutical Co.,...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Zhejiang Huayi Pharmaceutical Co.,...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Sichuan Kelun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Sichuan Kelun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Natco Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Natco Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WCarrow-down NDC KDMF arrow-down VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-08-14

Pay. Date : 2023-05-08

DMF Number : 38197

Submission : 2023-04-26

Status : Active

Type : II

blank

02

Hetero Labs Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

02

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2016-07-06

Pay. Date : 2016-05-02

DMF Number : 30490

Submission : 2016-05-13

Status : Active

Type : II

blank

03

PEGS Boston Summit
Not Confirmed

03

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36838

Submission : 2022-03-30

Status : Active

Type : II

blank

04

PEGS Boston Summit
Not Confirmed

04

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2016-01-21

Pay. Date : 2015-11-06

DMF Number : 29870

Submission : 2015-11-03

Status : Active

Type : II

blank

05

PEGS Boston Summit
Not Confirmed

05

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2025-11-07

Pay. Date : 2025-09-08

DMF Number : 41596

Submission : 2025-09-28

Status : Active

Type : II

blank

06

PEGS Boston Summit
Not Confirmed

06

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42842

Submission : 2025-10-27

Status : Active

Type : II

blank

07

PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39898

Submission : 2024-04-27

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content

Regorafenib

About the Company : Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, ant...

Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, antibiotics, ARVs, CNS, and cardiovascular segments. The company operates facilities approved by US FDA, EDQM, Health Canada, and WHO-GMP, supported by multiple global DMFs and Ecovadis recognition. Backed by strong R&D, global patents, and customer-focused practices, Maithri delivers high-quality APIs with regulatory excellence. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib

About the Company : Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004. The company is located in Chongqing Changshou Economic and Technological Development Zone, covering an a...

Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004. The company is located in Chongqing Changshou Economic and Technological Development Zone, covering an area of about 100 acres, a construction area of over 30,000 square meters, and a registered capital of 1.189 billion yuan. It is the first company in Changshou Economic and Technological Development Zone successfully listed on the Shenzhen GEM. The company has 9 wholly-owned and holding subsidiaries. In March 2008, Fuan Pharmaceutical Group Chongqing Lybon Pharm-Tech Co
blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
blank

04

Natco Pharma

India
PEGS Boston Summit
Not Confirmed
arrow

Natco Pharma

India
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib

About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...

NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, NATCO today has five manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.NATCO family currently consists of more than 2500 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. NATCO is well recognized for its innovation in Pharmaceutical R&D.
blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib Monohydrate

About the Company : Parsian Pharmaceutical is dedicated to improving health outcomes by offering high-quality, effective pharmaceutical products. With a strong commitment to research, innovation, and ...

Parsian Pharmaceutical is dedicated to improving health outcomes by offering high-quality, effective pharmaceutical products. With a strong commitment to research, innovation, and quality, Parsian Pharmaceutical develops and manufactures a broad range of medications designed to meet international standards and address diverse therapeutic needs. Serving both local and global markets, Parsian Pharmaceutical strives to be a trusted healthcare partner, providing reliable, accessible solutions that enhance patient care and contribute to a healthier society.
blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib

About the Company : Sai Phytoceuticals Pvt. Ltd. Is an ISO 9001:2000 and HACCP certified company established in 2002. The core business of the company focuses on manufacturing and marketing (for domes...

Sai Phytoceuticals Pvt. Ltd. Is an ISO 9001:2000 and HACCP certified company established in 2002. The core business of the company focuses on manufacturing and marketing (for domestic as well as In- ternational markets) of a variety of plant based products categorised broadly as Anti-cancer Products, Phytoceuticals, cus- tom synthesized synthetic intermediates and API’s
blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib

About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...

Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of range like pharmaceuticals, agrochemicals, electronic chemicals, surfactants and other specialty chemicals.
blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

regorafenib monohydrate

About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...

Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of range like pharmaceuticals, agrochemicals, electronic chemicals, surfactants and other specialty chemicals.
blank

09

Sterling Spa

Italy
PEGS Boston Summit
Not Confirmed
arrow

Sterling Spa

Italy
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib

About the Company : The Quality Assurance department is the Guardian of Quality within the Company. We have a team dedicated to identifying and implementing new ICH guidelines. Our team is prepared ...

The Quality Assurance department is the Guardian of Quality within the Company. We have a team dedicated to identifying and implementing new ICH guidelines. Our team is prepared to obtain quality objectives which have been universally recognized by Inspection Authorities and the most important Pharmaceutical Companies from around the globe. This system is periodically verified through internal, national and international inspectors who have been able to recognize the high level obtained by the system and the actual achievement of quality objectives multiple times. Sterling has been inspected three times by FDA .
blank

10

Viatris

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Viatris

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Regorafenib

About the Company : In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (N...

In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Lubricants & Glidants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Granulation

read-more
read-more

Direct Compression

read-more
read-more

Controlled & Modified Release

read-more
read-more

Co-Processed Excipients

read-more
read-more

Solubilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Emulsifying Agents

read-more
read-more

Parenteral

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

API Stability Enhancers

read-more
read-more

Topical

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 755037-03-7 / Regorafenib API manufacturers, exporters & distributors?

Regorafenib manufacturers, exporters & distributors 1

42

PharmaCompass offers a list of Regorafenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Regorafenib manufacturer or Regorafenib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Regorafenib manufacturer or Regorafenib supplier.

API | Excipient name

Regorafenib

Synonyms

755037-03-7, Bay 73-4506, Stivarga, 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-n-methylpicolinamide, Regorafenibum, Regorafenib (bay 73-4506)

Cas Number

755037-03-7

Unique Ingredient Identifier (UNII)

24T2A1DOYB

About Regorafenib

Regorafenib is the anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.

Stivarga Manufacturers

A Stivarga manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Stivarga, including repackagers and relabelers. The FDA regulates Stivarga manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Stivarga API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Stivarga manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Stivarga Suppliers

A Stivarga supplier is an individual or a company that provides Stivarga active pharmaceutical ingredient (API) or Stivarga finished formulations upon request. The Stivarga suppliers may include Stivarga API manufacturers, exporters, distributors and traders.

click here to find a list of Stivarga suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Stivarga USDMF

A Stivarga DMF (Drug Master File) is a document detailing the whole manufacturing process of Stivarga active pharmaceutical ingredient (API) in detail. Different forms of Stivarga DMFs exist exist since differing nations have different regulations, such as Stivarga USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Stivarga DMF submitted to regulatory agencies in the US is known as a USDMF. Stivarga USDMF includes data on Stivarga's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Stivarga USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Stivarga suppliers with USDMF on PharmaCompass.

Stivarga KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Stivarga Drug Master File in Korea (Stivarga KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Stivarga. The MFDS reviews the Stivarga KDMF as part of the drug registration process and uses the information provided in the Stivarga KDMF to evaluate the safety and efficacy of the drug.

After submitting a Stivarga KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Stivarga API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Stivarga suppliers with KDMF on PharmaCompass.

Stivarga CEP

A Stivarga CEP of the European Pharmacopoeia monograph is often referred to as a Stivarga Certificate of Suitability (COS). The purpose of a Stivarga CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Stivarga EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Stivarga to their clients by showing that a Stivarga CEP has been issued for it. The manufacturer submits a Stivarga CEP (COS) as part of the market authorization procedure, and it takes on the role of a Stivarga CEP holder for the record. Additionally, the data presented in the Stivarga CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Stivarga DMF.

A Stivarga CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Stivarga CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Stivarga suppliers with CEP (COS) on PharmaCompass.

Stivarga WC

A Stivarga written confirmation (Stivarga WC) is an official document issued by a regulatory agency to a Stivarga manufacturer, verifying that the manufacturing facility of a Stivarga active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Stivarga APIs or Stivarga finished pharmaceutical products to another nation, regulatory agencies frequently require a Stivarga WC (written confirmation) as part of the regulatory process.

click here to find a list of Stivarga suppliers with Written Confirmation (WC) on PharmaCompass.

Stivarga NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Stivarga as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Stivarga API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Stivarga as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Stivarga and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Stivarga NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Stivarga suppliers with NDC on PharmaCompass.

Stivarga GMP

Stivarga Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Stivarga GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Stivarga GMP manufacturer or Stivarga GMP API supplier for your needs.

Stivarga CoA

A Stivarga CoA (Certificate of Analysis) is a formal document that attests to Stivarga's compliance with Stivarga specifications and serves as a tool for batch-level quality control.

Stivarga CoA mostly includes findings from lab analyses of a specific batch. For each Stivarga CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Stivarga may be tested according to a variety of international standards, such as European Pharmacopoeia (Stivarga EP), Stivarga JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Stivarga USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty